---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-037958"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:11:55.644095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials

## Summary
- Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
- Kairos to pay $900,000 for PreCheck's lab services using SolidTumorCheck+ platform.
- PreCheck will develop a companion diagnostic (three-gene PCR) for ENV105 to identify responsive patients.
- Target indications: EGFR-driven lung cancer resistant to osimertinib and castrate-resistant prostate cancer.
- Companion diagnostic to be submitted for FDA approval to guide Phase 3 patient selection.

## SEC filing metadata
- accession: 0001493152-24-037958
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315224037958/0001493152-24-037958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315224037958/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-037958
- JSON: https://secwatch.observer/filing/0001493152-24-037958.json
- Plain text: https://secwatch.observer/filing/0001493152-24-037958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.